БЛОКАДА ЦИТОКИНОВОГО ШТОРМА ПРИ ТЯЖЕЛОМ ТЕЧЕНИИ ИНФЕКЦИИ, ВЫЗВАННОЙ SARS-COV-2: МЕДИКАМЕНТОЗНАЯ СУПРЕССИЯ ИЛИ ЭКСТРАКОРПОРАЛЬНАЯ ЭЛИМИНАЦИЯ?



DOI: http://dx.doi.org/10.25298/2221-8785-2020-18-5-505-512


Р. Э. Якубцевич

Аннотация


Введение. Актуальность проблемы лечения тяжелой формы COVID-19 обусловлена высокой летальностью как в общей популяции пациентов (6,4%), так и у пациентов отделений интенсивной терапии (25,8%). Цитокиновый шторм – патологическое состояние, приводящее к высокой летальности. Известны 2 подхода к снижению воспалительных цитокинов в крови: блокада их выработки медикаментозными препаратами и экстракорпоральное удаление. Однако выбор того или иного подхода остается предметом дискуссий. Цель. Провести анализ литературы по современным подходам к назначению лекарственных средств и экстракорпоральной детоксикации для блокады цитокинового шторма при тяжелой инфекции COVID-19. Материал и методы. Проанализировано 47 литературных источников. Результаты. Получены сведения о современных методах блокады цитокинового шторма при тяжелой инфекции COVID-19, указывающих как на эффективность тоцилизумаба, так и селективной антицитокиновой гемосорбции, плазмафереза, методов почечно-заместительной терапии.Выводы. На основе клинических наблюдений установлено, что не только медикаментозная супрессия воспалительных цитокинов может быть эффективна в лечении тяжелых COVID-19 пневмоний, эффективны также и методы экстракорпорального очищения крови.

Ключевые слова


Sars-CoV-2; коронавирус; COVID-19; пневмония; острый респираторный дистресс-синдром; цитокины; экстракорпоральное очищение крови; гемосорбция; плазмаферез

Полный текст:

Литература


Coronavirus disease 2019 (COVID-19) : Situation Report 127 [Electronic resource] / World Health Organization. – Mode of access: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200526-covid-19-sitrep-127.pdf?sfvrsn$=$7b6655ab_8. – Date of access: 27.05.2020.

ICU and ventilator mortality among critically ill adults with COVID-19 : preprint 2020.04.23.20076737 : It is made available under a CC-BY-NC-ND 4.0 / S. Auld [et al.] // medRxiv. – 2020. – 12 p. – Mode of access: https://www.medrxiv.org/content/10.1101/2020.04.23.20076737v1.full.pdf. – doi: 10.1101/2020.04.23.20076737.

Clinical features of patients infected with 2019 novel coro-navirus in Wuhan, China / C. Huang [et al.] // Lancet. – 2020. – Vol. 395, iss. 10223. – P. 497-506. – doi: 10.1016/S0140-67362030183-5.

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China / Q. Ruan [et al.] // Intensive Care Med. – 2020. – Vol. 46, iss. 5. – P. 846-848. – https://doi.org/10.1007/s00134-020-05991-x.

Clinical and immunologic features in severe and moder-ate Coronavirus Disease 2019 / G. Chen [et al.] // J. Clin. Invest. – 2020. – Vol. 130, iss. 5. – P. 2620-2629. – doi: 10.1101/2020.02.16.20023903.

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19 / Y. Gao [et al.] // J. Med. Virol. – 2020. – Vol. 92, iss. 7. – P. 791-796. – doi: 10.1002/jmv.25770.

Braciale, T. Immunity to viruses / T. Braciale, Y. Hahn // Immunol. Rev. – 2013. – Vol. 255, iss. 1. – P. 5-12. – doi: 10.1111/imr.12109.

The COVID-19 cytokine storm; What we know so far / D. Ragab [et al.] // Front. Immunol. – 2020. – Vol. 11. – P. 1446. – https://doi.org/10.3389/fimmu.2020.01446.

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study / N. Chen [et al.] // Lancet. – 2020. – Vol. 395, iss. 10223. – P. 507-513. – doi: 10.1016/S0140-67362030211-7.

Shimizu M. Clinical features of cytokine storm syndrome // Cytokine Storm Syndrome / ed.: R. Cron, E. Behrens. – Cham : Springer, 2019. – P. 31-42. – doi: 10.1007/978-3-030-22094-5_3.

Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever / A. Şahin [et al.] // Adv. Rheumatol. – 2020. – Vol. 60, iss. 1. – P. 12. – doi: https://doi.org/10.1186/s42358-020-0117-1.

Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: re-analysis of a prior phase III trial / B. Shakoory [et al.] // Crit. Care Med. – 2016. – Vol. 44, iss. 2. – P. 275-281. – doi: 10.1097/CCM.0000000000001402.

Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloi-dosis / O. Varan [et al.] // Mod. Rheumatol. – 2019. – Vol. 29, iss. 2. – P. 363-366. – https://doi.org/10.1080/14397595.2018.1457469.

COVID-19: combining antiviral and anti-inflammato-ry treatments / J. Stebbing [et al.] // Lancet. Infect. Dis. – 2020. – Vol. 20, iss. 4. – P. 400-402. – doi: 10.1016/S1473-3099(20)30132-8.

COVID-19: the new challenge for rheumatologists / F. Ferro [et al.] Clin. Exp. Rheumatol. – 2020. – Vol. 38, iss. 2. – P. 175-180.

Management of cytokine release syndrome related to CAR-T cell therapy / H. Chen [et al.] // Front. Med. – 2019. – Vol. 13, iss. 5. – P. 610-617. – doi: 10.1007/s11684-019-0714-8.

Effective treatment of severe COVID-19 patients with Tocilizumab / X. Xu [et al.] // Proc. Nat. Acad. Sci USA. – 2020. – Vol. 117, iss. 20. – P. 10970-10975. – doi: 10.1073/pnas.2005615117.

Jones, G. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis / G. Jones, C. Ding. // Clin. Med. Insights Arthritis Musculoskelet. Dis. – 2010. – Vol. 3. – P. 81-89. –https://doi.org/10.4137/CMAMD.S4864.

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? / S. Antinori [et al.] // Autoimmun. Rev. – 2020. – Vol. 19, iss. 7. – P. 102564. – doi: 10.1016/j.autrev.2020.102564.

Treat 2019 novel coronavirus (COVID-19) with IL-6 in-hibitor: Are we already that far? / Y. Zhang [et al.] // Drug Discov. Ther. – 2020. – Vol. 14, iss. 2. – P. 100-102. – doi: 10.5582/ddt.2020.03006.

Ronco, C. Sepsis: theory and therapies / C. Ronco, R. Bellomo, G. Lonneman // N. Engl. J. Med. – 2003. – Vol. 348, iss. 16. – P. 1600-1602. – doi: 10.1056/NEJM200304173481616.

Potential effect of blood purification therapy in reduc-ing cytokine storm as a late complication of critically ill COVID-19 / J. Ma [et al.] // Clin. Immunol. – 2020. – Vol. 214. – P. 108408. – doi:10.1016/j.clim.2020.108408.

Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 pandemic: expert review and recommendation / C. Ronco [et al.] // Blood Purification. – 2020. – P. 1-11. – doi: 10.1159/000508125.(Epub ahead of print).

Emergency Use Authorizations for Medical Devices [Electronic resource] / FDA. – Mode of access: https://www.fda.gov/medical-devices/emergency-situations-med-ical-devices/emergency-use-authorizations. – Date of ac-cess: 27.05.2020.

Relationship between alternative resuscitation strategies, host response and injury biomarkers, and outcome in sep-tic shock: analysis of the protocol-based care for early septic shock study / J. A. Kellum [et al.] // Crit. Care Med. – 2017. –Vol. 45, iss. 3. – P. 438-445. – doi: 10.1097/CCM.0000000000002206.

Early hemoperfusion for cytokine removal may contrib-ute to prevention of intubation in patients infected with COVID-19 / E. Esmaeili Vardanjani [et al.] // Blood Purif. – 2020. – P. 1-4. – doi: 10.1159/000509107. (Epub ahead of print).

Journal of the Grodno State Medical University, Vol. 18, No 5, 2020 510

CytoResc - “CytoSorb” rescue for critically ill patients undergoing the COVID-19 cytokine storm: a structured summary of a study protocol for a randomized controlled trial / H. Stockmann [et al.] // Trials. – 2020. – Vol. 21, iss. 1. – P. 577. – doi: 10.1186/s13063-020-04501-0.

Napp, L. C. Extracorporeal hemoadsorption an option for COVID-19 associated cytokine storm syndrome / L. C. Napp, J. Bauersachs // Shock. – 2020. – doi: 10.1097/SHK.0000000000001568. (Epub ahead of print).

Management of patients on dialysis and with kidney trans-plant during COVID-19 coronavirus infection / F. Alberici [et al.] // G. Ital. Nefrol. – 2020. – Vol. 37, iss. 2 – P. 1-6. – doi: 10.22141/2307-1257.9.2.2020.203411.

A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 / P. Keith [et al.] // Crit. Care. – 2020. – Vol. 24, iss. 1. – P. 128. – https://doi.org/10.1186/s13054-020-2836-4.

Endothelial cell infection and endotheliitis in COVID-19 / Z. Varga [et al.] // Lancet. – 2020. – Vol. 395, iss. 10234. – P. 1417-1418. – doi: 10.1016/S0140-6736(20)30937-5.

A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 / P. Keith [et al.] / Crit. Care. – 2020. – Vol. 24, iss. 1. – P. 128. – doi: 10.1186/s13054-020-2836-4.

First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19 / K. Stahl [et al.] // Crit. Care. – 2020. – Vol. 24, iss. 1. – P. 363. – doi: 10.1186/s13054-020-03070-7.

Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure / P.M. Honore [et al.] // Crit. Care. – 2020.– Vol. 24, iss. 1. –P. 226. – doi:10.1186/s13054-020-02943-1.

Padmanabhan, A. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the American Society for Apheresis: the eight special issue / A. Padmanabhan, L. Connelly-Smith, N. Aqui // J. Clin. Apher. – 2019. – Vol. 34, iss. 3. –P. 171-354. – https://doi.org/10.1002/jca.21705.

The successful use of therapeutic plasma exchange for se-vere COVID-19 acute respiratory distress syndrome with multiple organ failure / P. Keith [et al.] // SAGE Open Med. Case Rep. – 2020. – Vol. 8. – 2050313X20933473. – doi: 10.1177/2050313X20933473.

Plasmapheresis treatment in COVID-19-related autoim-mune meningoencephalitis: Case series / L. Dogan [et al.] // Brain Behav. Immun. – 2020. – Vol. 87. – P. 155-158. – doi: 10.1016/j.bbi.2020.05.022.

Application of plasma exchange in association with higher dose CVVH in cytokine storm complicating COVID-19 / J. H. Lin [et al.] // Med. Assoc. – 2020. – Vol. 119, iss. 6. – P. 1116-1118. – doi: 10.1016/j.jfma.2020.04.023.

Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab / S. Luo [et al.] // Zhejiang Da Xue Xue Bao Yi Xue Ban. – 2020. – Vol. 49, iss. 2. – P. 227-231. – doi: 10.3785/j.issn.1008-9292.2020.03.06.

Clinical characteristics of coronavirus disease 2019 in China / W. J. Guan [et al.] // N. Engl. J. Med. – 2020. – Vol. 382, iss. 18. – P. 1708-1720. – doi: 10.1056/NEJMoa2002032.

COVID-19 and renal failure: challenges in the delivery of renal replacement therapy / S. Adapa [et al.] // J. Clin. Med. Res. – 2020. – Vol. 12, iss. 5. – P. 276-285. – doi: 10.14740/jocmr4160.

Factors associated with acute kidney injury in acute respira-tory distress syndrome / A. Panitchote [et al.] // Ann. Intens. Care. – 2019. – Vol. 9. – P. 1-10. – https://doi.org/10.1186/s13613-019-0552-5.

Continues renal replacement therapy (CRRT) with dispos-able hemoperfusion cartridge: a promising option for se-vere COVID-19 / F. Dastan [et al.] // J. Glob. Antimicrob. Resist. – 2020. – Vol. 21. – P. 340-341. – doi: 10.1016/j.jgar.2020.04.024.

A continuous renal replacement therapy protocol for pa-tients with acute kidney injury in intensive care unit with COVID-19 / F. Nalesso [et al.] // J. Clin. Med. – 2020. – Vol. 9, iss. 5. – P. 1529. – doi: 10.3390/jcm9051529.

Clinical course and risk factors for mortality of adult pa-tients with COVID-19 in Wuhan, China: a retrospective cohort study / F. Zhou [et al.] // Lancet. – 2020. – Vol. 395. – P. 1054-1062. – doi: 10.1016/S0140-6736(20)30566-3.

A pneumonia outbreak associated with a new coronavirus of probable bat origin / P. Zhou [et al.] // Nature. – 2020. – Vol. 579. – P. 270-273. – doi: 10.1038/s41586-020-2012-7.

Effect of continuous renal replacement therapy on all-cause mortality in COVID-19 patients undergoing inva-sive mechanical ventilation: a retrospective cohort study : preprint / Y. Yang [et al.] // medRxiv. – 2020. – 22p. – doi: 10.1101/2020.03.16.20036780.


Ссылки

  • На текущий момент ссылки отсутствуют.